NovaBridge Biosciences (NBP) Stock

NovaBridge Biosciences (NBP) is a Healthcare stock trading at $2.00 (as of 2026-08-21), with a market capitalization of $530.76M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

NovaBridge Biosciences develops immuno-oncology therapeutics for cancer, including bispecific and monoclonal antibody candidates such as givastomig, ragistomig, and uliledlimab, as well as FE301 under a licensing arrangement. Its programs are focused on clinical development in the United States and are conducted with partners including Bristol Myers Squibb, ABL Bio, TJ Bio, and Ferring International Center SA.

Understand NovaBridge Biosciences: how it makes money

NovaBridge Biosciences develops immuno-oncology cancer therapies, primarily bispecific and immune-modulating antibody candidates, and it expects to earn money through licensing and collaboration arrangements tied to its pipeline.

Its profit model is driven by turning early clinical-stage antibody candidates into future monetization (via licensing, collaborations, and product supply), rather than by current core product sales.

Business quality (Unprofitable): Unprofitable, with operating margin -367% in the latest quarter.

Bull case

  • Broad immuno-oncology targeting: The company is advancing multiple immuno-oncology agents, including givastomig (bispecific antibody) in Phase 1b for gastric cancer and ragistomig (bispecific antibody) in Phase 1 for solid tumors. If clinical results support efficacy, that breadth could expand the number of paths to future value creation.
  • Licensing partnership supports scale: NovaBridge has a strategic licensing agreement with Ferring International Center SA covering FE301 research and commercialization activities. That structure can help support development progress and future monetization through partner-linked pathways.

Bear case

  • Losses are structurally large: Operating margin is -367% in the latest quarter, indicating expenses far outweigh revenue today. This makes the business highly sensitive to continued funding and to the timing of any future monetization.
  • Early-stage clinical risk remains: Its main assets are in Phase 1b or Phase 1, which means they are still early in the evidence-building process. If trial outcomes do not support continued development, commercialization timelines and any licensing value could be delayed or reduced.
Valuation — source: SEC EDGAR (first-party)
Price$2.00
Market Cap$530.76M
EV / EBITDA-3.4
Price / Book2.30
Price / Sales69.74
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$7.61M
Net Margin-607.9%
Return on Equity-20.0%
Current Ratio8.09
Revenue Growth (YoY)1.7%
EPS Growth (YoY)75.0%
Financial Health — source: SEC EDGAR
Altman Z-Score3.29 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJANUS HENDERSON GROUP PLC ($14.81M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOXi-Yong Fu
Employees32
CountryUS
IPO Date2020-01-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Evolus, Inc. (EOLS)
  • ARS Pharmaceuticals, Inc. (SPRY)
  • Ovid Therapeutics Inc. (OVID)
  • Sagimet Biosciences Inc. (SGMT)
  • Prelude Therapeutics Incorporated (PRLD)
  • MapLight Therapeutics, Inc. (MPLT)
  • Evommune, Inc. (EVMN)
  • XOMA Royalty Corp. (XOMA)
NBP earnings history · NBP institutional & insider holders · NBP KPIs & operating metrics · NBP financials · NBP investor presentations & press releases · NBP SEC filings · NBP peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.